Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

NCT02748213 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01940497 ·Status: COMPLETED ·Phase: PHASE3

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

NCT03734029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

NCT06928818 ·Status: RECRUITING

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 ·Status: RECRUITING ·Phase: NA

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

NCT00436566 ·Status: COMPLETED ·Phase: PHASE2

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

NCT05656079 ·Status: UNKNOWN ·Phase: NA

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

NCT00615602 ·Status: COMPLETED ·Phase: PHASE3

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255 ·Status: COMPLETED ·Phase: PHASE3

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

NCT00944047 ·Status: COMPLETED ·Phase: PHASE2

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915 ·Status: COMPLETED ·Phase: PHASE1

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

NCT01301729 ·Status: COMPLETED ·Phase: PHASE4

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365 ·Status: COMPLETED ·Phase: PHASE2

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy

NCT05019365 ·Status: UNKNOWN

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391 ·Status: COMPLETED ·Phase: PHASE2

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945 ·Status: RECRUITING ·Phase: PHASE3

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883 ·Status: RECRUITING ·Phase: PHASE2

Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients

NCT00429247 ·Status: COMPLETED ·Phase: PHASE2

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

NCT06585969 ·Status: WITHDRAWN ·Phase: PHASE3

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

NCT00950300 ·Status: COMPLETED ·Phase: PHASE3

Trastuzumab Deruxtecan in Advanced Breast Cancer

NCT07180264 ·Status: RECRUITING

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596 ·Status: TERMINATED ·Phase: PHASE2

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3